Tendons are dense connective tissues tethering skeletal muscles to bones that act as force transmission conduits for locomotion^[@R1]^. They bear enormous mechanical load owing to longitudinal alignment of specialized extracellular matrix deposited by tenocytes in the tendon midsubstance. Injuries to tendons represent the worst clinical outcome within the musculoskeletal system, as healed tendons rarely attain the integrity of undamaged state. A culprit for the inferiority of healed tendons is fibrotic scarring that disrupts tendon matrix continuity. As such, re-rupture is common, often necessitating reconstructive surgery and resulting in chronic pain and impaired mobility^[@R2],[@R3]^. Injury models have been developed in rodents to study tendon healing, ranging from complete failure after transection of the Achilles^[@R4],[@R5]^, fibrotic adhesions and scarring of flexor tendons^[@R6]--[@R10]^, to robust regeneration after biopsy punch-injury of the Patellar tendon^[@R11]^. Extensive histological data for tendon healing and fibrosis exist^[@R2]^, but the underlying cellular and molecular mechanisms remain elusive.

Tentative tendon stem/progenitors (TSPCs) have been studied *in vitro*^[@R4]^. Cells dissociated from tendon midsubstance form colonies in specifically formulated media^[@R12]^. These colonies give rise to fat, bone, and tendon-like structures after engraftment together with bone matrix. However, *in vivo* correspondence of these cells is unknown^[@R4],\ [@R12],\ [@R13]^. For *in vivo* stem cell identification, the tamoxifen-inducible Cre-ER^T2^ mediated lineage tracing^[@R14],\ [@R15]^ has gained recognition as a definitive approach. Past attempts to identify adult tendon stem cells by this approach made no firm conclusions thus far. A transgenic αSMA-CreER^T2^ labeled multiple cell types around Patellar tendon, but they were unlikely stem cells as they did not give rise to tenocytes with longitudinally aligned collagen matrix second harmonic generation (SHG) signals^[@R16]^. On the other hand, tenocytes labeled by the *Scleraxis* (*Scx*)-CreER^T2^ were able to regenerate transected Achilles in neonates but not in adults, indicating that tenocytes have regenerative potential limited to the perinatal period^[@R17]^. In these studies, either the Cre drivers did not mark tendon stem cells or the chosen injury paradigms prevented stem cells to regenerate. To better the odds of uncovering adult tendon stem cells, here we chose to use the regeneration-competent Patellar tendon punch-injury model^[@R11],\ [@R18],\ [@R19]^. We took a logical approach to characterize cell types in the adult Patellar tendon, followed by making Cre-ER^T2^ drivers to define *Tppp3*^+^ paratenon sheath cells^[@R20],\ [@R21]^ as tendon stem cells. By exploiting heterogeneity within the *Tppp3*^+^ tendon stem cell population, we determined the cellular and molecular mechanisms that inextricably link tendon stem cell-mediated regeneration and fibrosis via shared usage of PDGF signalling. Tools and results provided here for studying the Patellar tendon regeneration should facilitate future studies in other paratenon sheathed tendons and help inform translational strategies.

Results {#S1}
=======

Single cell analysis reveals heterogeneous composition in the Patellar tendon {#S2}
-----------------------------------------------------------------------------

Until now, a lack of a complete molecular cell atlas for adult tendon hampered our ability to identify tendon stem cells. To this end, we categorized the cells present in adult (\~ 3 month (M) old) Patellar tendons by single cell RNA-sequencing (scRNA-seq)^[@R22]^. Whole tendons were enzymatically dissociated for scRNA-seq. Of 2491 cells surveyed, 8 cell clusters were delineated by Cell Ranger ([Fig. 1a](#F1){ref-type="fig"}; [Supplementary Table 1](#SD14){ref-type="supplementary-material"}). By Satija lab's estimate (see [Methods](#S13){ref-type="sec"}) of our scRNA-seq data, we have uncovered cell types present at 1% in the tendon. These datasets were compared to NCBI deposited datasets and single cell mouse cell atlas for cell type assignment. Clusters 1, 5, 6, 7, and 8 represent red blood cells (RBCs), osteoblasts, endothelial cells, macrophages, and antigen-presenting cells (APCs), respectively. Cluster 3 cells showed corresponding expression ("overlap") of \~90% of the top 500 genes (GSE89633) expressed by fibro-adipogenic progenitors (FAPs) found in skeletal muscle^[@R23],\ [@R24]^; genes encoding positive (e.g. *Pdgfra* and *Ly6a*) and negative (e.g. *Cd45*, *Cd31*, and *Itga7*) markers used to define FAPs showed corresponding expression. Thus, we tentatively named them tendon-FAPs (T-FAPs). Cluster 4 cells are tenocytes as they express tendon-specific genes such as *Fibromodulin* (*Fmod*; ranked 3 of top 100 genes, *P* =1.43E-13)^[@R12],\ [@R25],\ [@R26]^, *Tenomodulin* (*Tnmd*; ranked 15 of top 100 genes, *P* = 5.63E-14) ^[@R27]^, and *Thrombospondin 4* (*Thbs4*; ranked 6 of top 100 genes, *P* = 5.63E-12)^[@R28]^. Cluster 2 is enriched for *Tppp3* (ranked 14 of top 100 genes, *P* = 1.46E-08) and expresses *Lubricin* (*Prg4*), which are reported to be expressed in tendon sheath cells^[@R20],\ [@R21],\ [@R29]^. The αSMA-lineage was reported to include several cell types around the Patellar tendon^[@R16]^, and indeed *Acta2 (*encoding αSMA) is expressed in many cell clusters ([Extended Data 1a](#F9){ref-type="fig"}). We performed immunofluorescence for representative markers for these cell clusters. Of the five markers examined, FMOD is in the midsubstance as expected. The others showed different patterns in the sheath, highlighting its complexity ([Fig. 1b](#F1){ref-type="fig"}; [Extended Data 1b](#F9){ref-type="fig"}).

*Tppp3*^+^ tendon sheath cells are found in the embryo to adulthood {#S3}
-------------------------------------------------------------------

Gene module similarity between the cluster 2 *Tppp3*^+^ cells and the cluster 4 tenocytes may be inferred by their proximity on the *t*-SNE plot. To explore whether a relationship exists between them, we re-engineered the [G]{.ul}al4 [t]{.ul}echnique for [r]{.ul}eal-time and [c]{.ul}lonal [e]{.ul}xpression (G-TRACE) design^[@R30]^ in mice: a CreER^T2^ and an eGFP reporter are inserted in the *Tppp3* locus (*Tppp3*^CG^) to identify *Tppp3*^+^ (eGFP^+^) cells and to indelibly mark the *Tppp3*-lineage with a Cre-reporter *R26R^tandem-Tomato^* (*R26R*^tdT^)^[@R15]^ by tamoxifen (TMX) in 3 M old adult mice ([Fig. 1c](#F1){ref-type="fig"}, [Extended Data 1c](#F9){ref-type="fig"}). eGFP was detected by antibody (not detectable without) in sheath cells next to the midsubstance. No tdT was detected without TMX. With TMX, 79.5 % of eGFP^+^ cells were labeled with tdT (eGFP^+^tdT^+^; [Extended Data 1d](#F9){ref-type="fig"}). While we focused on adult Patellar tendon regeneration in this study, we documented the presence of TMX-induced tdT^+^ cells in several paratenon sheathed tendons (Patellar, Achilles and tail) and a synovial sheathed tendon (flexor)^[@R31]^ at embryonic day 17.5 ([Extended Data 1e](#F9){ref-type="fig"}), and in Patellar tendon sheath at post-natal day 8 (P8) ([Extended Data 1f](#F9){ref-type="fig"}). When we lineage-traced them from perinatal stage to adulthood (P5 to P8, P30 and P90), they remain in the sheath ([Extended Data 1g](#F9){ref-type="fig"}) and minimally incorporate into the midsubstance during tendon growth period ([Extended Data 1h](#F9){ref-type="fig"}). Finally, we assessed how these cells behave in the adult Patellar tendon when marked at P90 and chased up to 10 M ([Fig. 1d](#F1){ref-type="fig"}), and found no changes in the proportion of labeled cells in sheath and midsubstance ([Fig. 1d](#F1){ref-type="fig"}, [Extended Data 1i](#F9){ref-type="fig"}). Daily 5-Ethynyl-2'-deoxyuridine (EdU) to record proliferation for 1 M following labeling resulted in 5.4 ± 0.4 % (mean±SEM, n=4) tdT^+^EdU^+^ cells. These data indicate that *Tppp3*^+^ cells are present in embryonic and persist to adult Patellar tendon sheath where they are largely quiescent, and do not contribute to the midsubstance during homeostatic state.

Tppp3^+^ population harbors tendon stem cells {#S4}
---------------------------------------------

To determine whether *Tppp3*^+^ cells respond to injury, we used a biopsy punch^[@R11],\ [@R18],\ [@R19]^ to injure the Patellar tendon for reliable regenerative outcome ([Fig. 1e](#F1){ref-type="fig"}, [f](#F1){ref-type="fig"}; [Extended Data 1j](#F9){ref-type="fig"}), and analyzed tendons 30 [d]{.ul}ays [p]{.ul}ost [i]{.ul}njury (dpi); EdU was administered for the first 15 d ([Fig. 1e](#F1){ref-type="fig"}). Most eGFP^−^tdT^+^ (*Tppp3*-off) cells infiltrated the midsubstance, aligned longitudinally ([Fig. 1f](#F1){ref-type="fig"}), proliferated (EdU^+^), and embedded in FMOD and TENASCIN-C (TNC) matrix proteins ([Fig. 1g](#F1){ref-type="fig"}, [Extended Data 1k](#F9){ref-type="fig"}--[m](#F9){ref-type="fig"}); few eGFP^−^tdT^+^ cells were found in the sheath. Thus, replicative descendants of eGFP^+^tdT^+^ sheath cells can assume tenocyte-like properties; uninjured controls showed minimal infiltration of eGFP^−^tdT^+^ cells to the midsubstance. Most eGFP^+^tdT^+^ cells overlying the regenerated midsubstance had proliferated and expressed no FMOD and TNC, indicating they were renewed stem cells. Together, *Tppp3*^+^ cells act as injury-responsive tendon stem cells for paratenon sheathed tendons.

*Tppp3*^+^ stem cell-mediated regeneration occurs largely in the first month {#S5}
----------------------------------------------------------------------------

We next sought to understand the cellular dynamics of how *Tppp3*^+^ stem cells orchestrate regeneration. To allow simultaneous monitoring of *Scx* expression (for tenocytes) in *Tppp3*-lineage, we generated *Tppp3*^ECE^, a knock-in allele with ER^T2^-flanked Cre driven by *Tppp3*, for lineage-marking with *R26R*^tdT^ that can be used in combination with a ScxGFP reporter^[@R31]^ expressed in the midsubstance ([Fig. 2a](#F2){ref-type="fig"}, [Extended Data 2a](#F10){ref-type="fig"}). We subjected the Patellar tendon to fluorescent multiphoton imaging for 3D-reconstruction at cellular resolution; in parallel, second harmonic generation (SHG) was recorded to visualize the midsubstance collagen matrix. Without injury, ScxGFP^+^ cells localized deep within the SHG^+^ domain while *Tppp3*-tdT^+^ cells, superficially ([Fig. 2a](#F2){ref-type="fig"}). Upon injury, tdT^+^ScxGFP^+^ and tdT^+^ScxGFP^−^ cells over the injured region increased dramatically from 3 to 7 dpi ([Fig. 2a](#F2){ref-type="fig"}). At 14 dpi, tdT^+^ScxGFP^+^ cells were seen deep within SHG^+^ domain and aligned with the longitudinal axis, whereas most tdT^+^ScxGFP^−^ cells were superficial ([Fig. 2a](#F2){ref-type="fig"}).

To monitor proliferation kinetics, we administered EdU in timed windows during regeneration ([Fig. 2b](#F2){ref-type="fig"}). Cell proliferation occurred primarily within the first 14 d (peaking at 7 dpi) and minimally at 28 dpi for both the sheath ([Fig. 2b](#F2){ref-type="fig"}, [Extended Data 2b](#F10){ref-type="fig"}) and midsubstance ([Extended Data 2c](#F10){ref-type="fig"}, [d](#F10){ref-type="fig"}) in the regenerated region. Accumulation of tdT^+^ cells in sheath and midsubstance followed the proliferation pattern. Transient high density of EdU^+^tdT^+^ScxGFP^+^ cells in the sheath at 7 dpi and the presence of EdU^+^tdT^+^ScxGFP^−^ and EdU^+^tdT^−^ScxGFP^+^ cells in the midsubstance were found ([Extended Data 2c](#F10){ref-type="fig"}, [d](#F10){ref-type="fig"}). Given the labeling efficiency of *Tppp3*^ECE^ ([Extended Data legends 1c](#F9){ref-type="fig"}, [2a](#F10){ref-type="fig"}), EdU^+^tdT^−^ScxGFP^+^ cells might be derived from unmarked *Tppp3*^+^ cells; however, it is possible that some midsubstance tdT^−^ScxGFP^+^ cells can proliferate, as suggested by prior studies^[@R32],\ [@R33]^. Together with the 3D data, we surmise that proliferative *Tppp3*-tdT^+^ cells either turn on ScxGFP prior to entering the midsubstance or enter the midsubstance without turning on ScxGFP, and that some tdT^−^ScxGFP^+^ cells also migrate to and proliferate in the damaged region for repair ([Fig. 2a](#F2){ref-type="fig"}, [b](#F2){ref-type="fig"}). By 14 dpi, compartmental boundaries are re-established: tdT^+^ScxGFP^−^EdU^+^ (renewed stem cells) in the sheath and tdT^+^ScxGFP^+^EdU^+^ (*de novo* tenocytes) in the midsubstance ([Fig. 2b](#F2){ref-type="fig"}; [Extended Data 2c](#F10){ref-type="fig"}, [d](#F10){ref-type="fig"}).

When we administered EdU after injury for 30 d, EdU^+^tdT^+^ScxGFP^−^ cells were found in the sheath ([Extended Data 2e](#F10){ref-type="fig"}). Given that proliferation ceased by 28 dpi ([Fig. 2b](#F2){ref-type="fig"}), they were renewed stem cells, consistent with the results by G-TRACE ([Fig. 1g](#F1){ref-type="fig"}). G-TRACE mice with EdU administered for only the first 15 d showed EdU retention in eGFP^+^tdT^+^ sheath cells at 30 dpi , indicating that self-renewal coincides with the major proliferation period (7-14 dpi). To determine whether tdT^+^ScxGFP~r~^+^ (along with tdT^+^ScxGFP^−^~r~ and tdT^−^ScxGFP~r~^+^; r, for regenerated) cells are tenocytes, we isolated them at 30 dpi by fluorescent activated cell sorting (FACS) for RNA-seq ([Fig. 2c](#F2){ref-type="fig"}, [Extended Data 2f](#F10){ref-type="fig"}). Indeed, tdT^+^ScxGFP~r~^+^ cells shared 95% of their transcriptome with unmarked tdT^−^ScxGFP~r~^+^ tenocytes ([Fig. 2d](#F2){ref-type="fig"}). Expectedly, they express tendon-specific transcription factors and matrix genes at equivalent levels ([Fig. 2e](#F2){ref-type="fig"}), but at higher levels than tdT^+^ScxGFP~r~^−^ cells ([Extended Data 2g](#F10){ref-type="fig"}). The transcriptomes of tdT^+^ScxGFP^−^~r~ and uninjured tdT^+^ (*Tppp3*^+^) cells are highly similar ([Fig. 2f](#F2){ref-type="fig"}), indicative of self-renewal of the former. Additionally, tdT^+^ScxGFP~r~^+^ cells are distinct from uninjured tdT^+^ (*Tppp3*^+^) cells, indicating these tenogenic *Tppp3*-descendants no longer bear a stem cell signature ([Extended Data 2h](#F10){ref-type="fig"}). Taken together, the *Tppp3*-lineage can proliferate, give rise to tenocytes in the midsubstance and self-renew in the sheath.

Comparison of tendon subpopulations unveils a potential role for PDGF signalling {#S6}
--------------------------------------------------------------------------------

We analyzed the transcriptomes of tdT(*Tppp3*)^+^ScxGFP^−^ and tdT^−^ScxGFP^+^ cells for differentially enriched genes and pathways ([Fig. 3a](#F3){ref-type="fig"}). We uncovered markers such as *Lama4*, *Ly6a*/*e*, and *Plin2* for tdT^+^ScxGFP^−^ stem cells ([Fig. 3b](#F3){ref-type="fig"}; [Extended Data 3a](#F11){ref-type="fig"}), but a recently reported sheath marker, Osteocalcin^[@R21]^, was not detected, nor in any cell cluster from scRNA-seq. We also found additional matrix biosynthesis and collagen genes in tdT^−^ScxGFP^+^ tenocytes not previously reported^[@R26],\ [@R27]^ ([Extended Data 3b](#F11){ref-type="fig"}). We next searched for a signalling pathway enriched in *Tppp3*-tdT^+^ScxGFP^−^ stem cells for further investigation. Through Gene Ontology (GO)-term analysis, we identified several signalling pathway components, some implicated in tenogenesis. Signalling components of Wnt^[@R34]^, IGF, Integrin are enriched in tenocytes; of TNF in stem cells; of TGF*β*^[@R35]^ in both; of Hedgehog in either^[@R28],\ [@R35]--[@R37]^ ([Extended Data 3c](#F11){ref-type="fig"}). However, no receptors of these pathways were enriched in stem cells. Ingenuity Pathway Analysis (IPA; [Extended Data 3d](#F11){ref-type="fig"}) identified additional enriched signalling pathways. In particular, *Pdgfra* for PDGF signalling is enriched in stem cells, whereas *Pdgfa* and the decoy PDGF receptor, *Pdgfrl*, are enriched in tenocytes ([Fig. 3b](#F3){ref-type="fig"}). Although Erk, PI3K, and Akt signalling is downstream of many pathways, their enrichment is consistent with PDGF signalling^[@R38]^. The differential expression of *Pdgfa*, *Pdgfrl*, and *Pdgfra* suggests a cross-compartmental regulation of tendon stem cell biology.

Yet, *Pdgfra* is one of the enriched genes used to assign cluster 3 T-FAPs by scRNA-seq ([Fig 1a](#F1){ref-type="fig"}; [Supplementary Table 1](#SD14){ref-type="supplementary-material"}). We re-examined the cluster 2 dataset and found that 50.6% of *Tppp3*^+^ cells co-express *Pdgfra* ([Fig. 3c](#F3){ref-type="fig"}). Knowing that cluster 2 *Tppp3*^+^ population contains stem cells for cluster 4 tenocytes, we used *Monocle 2* unsupervised pseudotime^[@R39]^ to model the relationship between these two clusters, which revealed 5 states ([Fig. 3d](#F3){ref-type="fig"}). There exist 3 *Tppp3*^+^ states (states 1, 2, 4) linked to tenocyte fate (state 5). State 1 represents *Tppp3*^+^*Pdgfra*^+^ cells and expresses higher levels of *Tppp3* than states 2 and 4. States 2 and 4 *Tppp3*^+^*Pdgfra*^−^ cells do not display notable gene expression composite (see RNA-seq data for *Tppp3*^+^*Pdgfra*^−^ cells below). Conversely, state 1 cells express high levels of sheath markers which show a downward trend via the intermediate state 3 towards state 5 ([Fig. 3d](#F3){ref-type="fig"}, [Extended Data 3e](#F11){ref-type="fig"}, [4a](#F12){ref-type="fig"}). Pseudotime projection from state 1 to 5 hints that *Tppp3*^+^*Pdgfra*^+^ is the tendon stem cell state.

*Tppp3*^+^*Pdgfra*^+^ cells are tenogenically predisposed and partially resemble T-FAPs {#S7}
---------------------------------------------------------------------------------------

To confirm *Tppp3^+^Pdgfra^−^*, *Tppp3^−^Pdgfra*^+^ and *Tppp3^+^Pdgfra*^+^ subpopulations in the sheath, we combined *Pdgfra*^H2B-eGFP^ (ref. [@R40]) and *Tppp3*^CG^*;R26R*^tdT^ alleles (referred to as *Tppp3*^CG^*;Pdgfra*^H2B-eGFP^; see [Methods](#S13){ref-type="sec"}) to delineate them. tdT^−^H2B-eGFP^+^and tdT^+^H2B-eGFP^−^ cells were indeed present. Furthermore, we found 61% of tdT^+^ cells were H2B-eGFP^+^ (i.e. Tppp3^+^Pdgfra^+^) in the Patellar tendon sheath ([Fig. 3e](#F3){ref-type="fig"}, [3f](#F3){ref-type="fig"}); minimal H2B-eGFP signal was found in midsubstance cells. tdT^−^H2B-eGFP^+^ and tdT^+^H2B-eGFP^−^ cells were present. Similar results were found by using *Tppp3*^ECE^*;R26R*^tdT^ combined with *Pdgfra*^H2B-eGFP^(*Tppp3*^ECE^*;Pdgfra*^H2B-eGFP^) ([Extended Data 4b](#F12){ref-type="fig"}, [c](#F12){ref-type="fig"}). These 3 subpopulations exist in different proportions in the paratenon sheath of Achilles and tail tendons ([Extended Data 4d](#F12){ref-type="fig"}). Labeling efficiencies of tdT within the TPPP3^+^H2B-eGFP^+^ population by *Tppp3*^ECE^ and *Tppp3*^CG^ drivers were determined at 56.1% and 77.0%, respectively ([Extended Data 4e](#F12){ref-type="fig"}).

To assess differences between *Tppp3*^+^*Pdgfra*^−^ and *Tppp3*^+^*Pdgfra*^+^ subpopulations, we performed RNA-seq on FACS-isolated tdT^+^H2B-eGFP^−^ and tdT^+^H2B-eGFP^+^ cells, respectively ([Fig. 4a](#F4){ref-type="fig"}). tdT^+^H2B-eGFP^−^ cells (i.e. cells in states 2 and 4 combined, in [Fig. 3d](#F3){ref-type="fig"}) bear no resemblance to FAPs nor tenogenic markers except for *Scx*. Their *Scx* expression level is considerably lower than that of tenocytes; we are unable to assign them to a known cell type to date. By contrast, tdT^+^H2B-eGFP^+^ cells expressed the majority of genes in state 1 ([Figs. 4b](#F4){ref-type="fig"} and [3d](#F3){ref-type="fig"}), showing the consistency between scRNA-seq and RNA-seq. Surprisingly, tdT^+^H2B-eGFP^+^ cells express markers for both FAPs and tenocytes ([Fig. 4c](#F4){ref-type="fig"}). Compared to tdT^−^ScxGFP^+^ tenocytes, tenogenic gene expression is lower in tdT^+^H2B-eGFP^+^ cells ([Fig. 4d](#F4){ref-type="fig"}, [e](#F4){ref-type="fig"}), likely reflecting an early activation state during cell dissociation and FACS isolation. Thus, we propose that tdT^+^H2B-eGFP^+^, i.e. *Tppp3^+^Pdgfra^+^,* cells are tendon stem cells.

*Tppp3*^−^*Pdgfra*^+^ (T-FAP) cells underlie tendon injury-associated fibrosis {#S8}
------------------------------------------------------------------------------

To test whether *Tppp3*^+^*Pdgfra*^+^ cells are indeed tendon stem cells, we examined their contribution to regeneration in *Tppp3*^ECE^;*Pdgfra*^H2B-eGFP^ mice. In this setting, H2B-eGFP was presumed lineage-inherited from *Pdgfra*^+^ cells. Following injury, 85% of the regenerated *Tppp3*-lineage in the midsubstance was tdT^+^H2B-eGFP^+^, incorporated EdU, and oriented in linear arrays, indicative of new tenocytes ([Fig. 4f](#F4){ref-type="fig"}). *Tppp3*^−^*Pdgfra*^+^ T-FAPs and *Tppp3*^+^*Pdgfra*^−^ cells also proliferated and entered the regenerated region. Proliferation indices of these 3 subpopulations indicate that they have similar kinetics ([Extended Data 4f](#F12){ref-type="fig"}). We suspected that T-FAPs gave rise to fibroblasts. To test this, we stained injured *Tppp3*^CG^*;R26R*^tdT^ tendon with ER-TR7, an antibody against reticular fibroblasts. A large proportion of ER-TR7^+^ fibroblasts were non-tdT-marked cells in both sheath and midsubstance in the injured area compared to uninjured area ([Fig. 4g](#F4){ref-type="fig"}), indicating that fibrotic cells rarely arise from the *Tppp3*-lineage. By contrast, in the injured *Tppp3*^ECE^*;Pdgfra*^H2B-eGFP^ tendon ([Fig. 4h](#F4){ref-type="fig"}), most ER-TR7^+^ cells in the injury area were tdT^−^H2B-eGFP^+^ ([Fig. 4i](#F4){ref-type="fig"}), supporting that T-FAPs contribute to tendon fibrosis. A subset of ER-TR7^+^ cells were also *Tppp3*^+^*Pdgfra*^+^, indicating that some of them assumed fibrogenic fate. By contrast, *Tppp3*^+^*Pdgfra*^−^ (i.e. tdT^+^H2B-eGFP^−^) cells rarely became fibroblasts or tenocytes.

PDGF-AA drives both tenogenesis and fibrosis {#S9}
--------------------------------------------

To test whether PDGFRα signalling plays a role in generating tenocytes, we applied PDGF-AA, which only activates PDGFRα^[@R38]^, to the Patellar tendon via GelFoam implants ([Fig. 5a](#F5){ref-type="fig"}, [b](#F5){ref-type="fig"}). Sheath cells showed an increase of EdU incorporation by PDGF-AA, relative to PBS and no GelFoam controls ([Fig. 5c](#F5){ref-type="fig"}). We next used the *Tppp3*^ECE/+^;*R26R*^tdT^;ScxGFP mice to compare the effects of PDGF-AA and PDGF-DD (which activates PDGFRβ^[@R40]^) ([Fig 5b](#F5){ref-type="fig"}, [d](#F5){ref-type="fig"}, [e](#F5){ref-type="fig"}). PDGF-AA and -DD, relative to PBS, increased EdU incorporation of *Tppp3*-lineage ([Fig. 5d](#F5){ref-type="fig"}), but only PDGF-AA induced ScxGFP expression in the sheath ([Fig. 5d](#F5){ref-type="fig"}) and deposition of tdT^+^ScxGFP^+^ cells in the midsubstance ([Fig. 5e](#F5){ref-type="fig"}, [Extended Data 4g](#F12){ref-type="fig"}), where they expressed FMOD ([Fig. 5f](#F5){ref-type="fig"}). Thus, ectopic PDGF-AA direct *Tppp3*^+^ cells to replicate and generate tenocytes. PDGF-AA also caused a concomitant increase in unmarked ER-TR7^+^ sheath cells compared to PBS control ([Fig. 5g](#F5){ref-type="fig"}). Thus, PDGFRα signalling directs both tenocyte generation and fibrosis.

PDGFRα signalling is required in *Tppp3*^+^ cells for tendon regeneration {#S10}
-------------------------------------------------------------------------

While *Tppp3*^+^*Pdgfra*^+^ cells can respond to exogenous PDGF-AA, whether they depend on PDGFRα signalling for homeostasis or regeneration is unclear. To test this, we used adult *Tppp3*^CG^;*Pdgfra*^fl/fl^ mice to inactivate *Pdgfra* (conditional Knock Out, cKO; [Fig. 6a](#F6){ref-type="fig"}). Without injury, cKO sheath cells did not show changes in marker expression up to 30 d ([Extended Data 5a](#F13){ref-type="fig"}). We then subjected them to injury and assessed regeneration at 30 dpi. At 30dpi, injured cKO tendon displayed gaps in matrix continuity and nuclear alignment ([Fig. 6a](#F6){ref-type="fig"}), mis-aligned collagen fibrils ([Fig. 6b](#F6){ref-type="fig"}) and gaps in TNC deposition ([Fig. 6c](#F6){ref-type="fig"}), compared to controls. By transmission electron microscopy ([Fig. 6d](#F6){ref-type="fig"}), we found that injured controls (CI) contained collagen fibrils with a shifted distribution towards sizes \< 70 nM in diameter compared to uninjured controls (CU). Injured cKO (cKO I) showed a structural gap devoid of fibrils, and a few fibrils adjacent to the gap of small diameter. *Tppp3*^ECE/+^;*Pdgfra*^fl/fl^ mice phenocopied *Tppp3*^CG^;*Pdgfra*^fl/fl^ mice ([Fig. 6c](#F6){ref-type="fig"}). To trace cKO cells, we included the *R26R*^tdT^ reporter (R-cKO); *Tppp3*^CG^;*R26R*^tdT^ mice were used as reporter-controls (R-control). As expected, R-cKO sheath cells were present without injury ([Extended Data 5b](#F13){ref-type="fig"}) and failed to regenerate following injury ([Fig. 7a](#F7){ref-type="fig"}). In the injured area, fewer R-cKO cells were found in sheath and midsubstance compared to R-control ([Fig. 7a](#F7){ref-type="fig"}; [Extended Data 5c](#F13){ref-type="fig"}). No programmed cell death was detected in R-cKO (see [Methods](#S13){ref-type="sec"}), indicating that the reduction of cells is mainly due to a proliferation defect. We delineated cell fractions according to proliferation history (EdU), and eGFP (*Tppp3*) and tdT (lineage) expression, and found that, relative to the R-control, a larger fraction of R-cKO cells were EdU^+^ and the majority of them, eGFP^+^tdT^+^. We suggest that *Tppp3*^+^*Pdgfra*^−^ and mutant cells stall at a progenitor state but are less robust to make new cells. In line with this, the majority of eGFP^+^tdT^+^ R-cKO cells are SCX^+^, while most R-control SCX^+^eGFP^−^tdT^+^ cells had turned off *eGFP* (i.e. *Tppp3*) as they differentiated into tenocytes ([Fig. 7b](#F7){ref-type="fig"}; [Extended Data 5d](#F13){ref-type="fig"}, [5e](#F13){ref-type="fig"}). Midsubstance R-cKO cells did not express FMOD ([Fig. 7c](#F7){ref-type="fig"}), indicating a defect in tenocyte differentiation. Additionally, R-cKO cells in the sheath were deficient in self-renewal as indicated by decreased eGFP^+^tdT^+^ cells. We conclude that *Pdgfra* is dispensable for SCX expression, potentiates proliferative capacity of tendon stem cells, and is essential for tenocyte differentiation (summarized in [Fig. 7d](#F7){ref-type="fig"}). We found an increase of unmarked ER-TR7^+^ cells in R-cKO compared to R-control ([Extended Data 5f](#F13){ref-type="fig"}), but no change in the tdT^+^ER-TR7^+^ cells between R-cKO and R-control. This suggests T-FAPs (*Tppp3*^−^*Pdgfra*^+^, hence unmarked) dominate in the regeneration-failure context of R-cKO, providing an explanation for extensive fibrosis in failed tendon regeneration.

Sheath subpopulations have stable and distinct properties *in vitro* {#S11}
--------------------------------------------------------------------

Next, we examined Tppp3^+^Pdgfra^+^, Tppp3^+^Pdgfra^−^, and Tppp3^−^Pdgfra^+^ cells *in vitro* in TSPC media using FACS-isolated tdT^+^H2B-eGFP^+^, tdT^+^H2B-eGFP^−^, and tdT^−^H2B-eGFP^+^ subpopulations, respectively, sorted to ≥ 98% purity ([Fig. 8a](#F8){ref-type="fig"}). Each subpopulation was sorted to [\>]{.ul} 98% purity and cultured in TSPC media^[@R12]^; tdT and H2B-eGFP signals were monitored, and TPPP3 and PDGFRα expression was determined ([Extended Data 6a](#F14){ref-type="fig"}, [b](#F14){ref-type="fig"}). tdT^+^H2B-eGFP^+^ subpopulation displayed no measurable changes in marker expression over time ([Fig. 8b](#F8){ref-type="fig"}). The tdT^−^H2B-eGFP^+^ ([Fig. 8c](#F8){ref-type="fig"}) and tdT^+^H2B-eGFP^−^ ([Fig. 8d](#F8){ref-type="fig"}) subpopulations did not decrease their proportions, and appeared to outcompete the contaminating tdT^+^H2B-eGFP^+^ cells over time. Thus, each subpopulation is stable in the condition used. We subjected each subpopulation to multipotential differentiation assays per mesenchymal stem cells (MSCs)^[@R41]--[@R43]^ ([Fig. 8a](#F8){ref-type="fig"}, [e](#F8){ref-type="fig"}). Like MSCs, tdT^−^H2B-eGFP^+^ (Tppp3^−^Pdgfra^+^) cells differentiated into adipogenic, chondrogenic, and osteogenic cells, whereas tdT^+^H2B-eGFP^+^ (Tppp3^+^Pdgfra^+^) gave rise to the latter two fates and tdT^+^H2B-eGFP^−^ (Tppp3^+^Pdgfra^−^) cells was only capable of chondrogenic fate ([Fig. 8e](#F8){ref-type="fig"}). Importantly, Tppp3^+^Pdgfra^+^ stem cells do not have adipogenic potential as TSPCs^[@R12]^. Tppp3^−^Pdgfra^+^ T-FAPs indeed have the same potentials as FAPs^[@R23],\ [@R24]^. As T-FAPs do not turn on TPPP3 *in vitro*, their switch to tendon stem cells *in vivo* is unlikely. As Tppp3^+^Pdgfra^−^ cells do not gain PDGFRα expression *in vitro*, they also may not become tendon stem cells *in vivo*. Implications of Tppp3^+^Pdgfra^−^ cells, Tppp3^−^Pdgfra^+^ T-FAPs, and Tppp3^+^Pdgfra^+^ tendon stem cells co-existing in the same niche are discussed below.

DISCUSSION {#S12}
==========

Here we present a logic-based approach to define adult tendon stem cells. We used paratenon sheathed Patellar tendon as a model for its well-established regenerative outcome^[@R11],\ [@R18],\ [@R19]^. scRNA-seq data support the complexity of tendon tissue noted previously^[@R44]--[@R47]^. From the data, we targeted the *Tppp3* gene to define tendon stem cells by lineage tracing, 3D imaging, and marker and histological analyses. RNA-seq data further provide evidence that *Tppp3*-lineage derived tdT^+^ScxGFP^+^ cells are *de novo* tenocytes. Tenocytes can also contribute to repair, albeit only in neonates^[@R17]^, which explains the derivation of *Scx*^+^CD34^−^ TSPCs from the midsubstance of young mice^[@R12]^. Contrasting to TSPCs, adult *Tppp3*^+^ tendon stem cells described herein express no *Scx* and high levels of *Cd34* (FPKM \>4000, based on RNA-seq) and are not in the midsubstance. The transcriptome of *Tppp3*^+^ cells may be exploited for prospective cell isolation via surface markers and further characterization. Importantly, we have defined a distinct tendon stem cell population *in vivo*.

By pseudotime^[@R39]^, we delineated *Tppp3*^+^*Pdgfra*^+^ and*Tppp3*^+^*Pdgfra*^−^ subpopulations. PDGFRα signalling is necessary and sufficient for *Tppp3*-lineage to produce new tenocytes, supporting *Tppp3*^+^*Pdgfra*^+^ as tendon stem cells. By contrast, the *Tppp3*^+^*Pdgfra*^−^ subpopulation rarely produce tenocytes, and their descendants are likely the tdT^+^ScxGFP^−^ cells found in the healing tendon. These 2 subpopulations were not resolved by Cell Ranger clustering using gene modules, but they showed differentially expressed genes by RNA-seq. This would indicate that they express similar gene modules to be clustered together but they are not the same, which explains their overlapping but not identical differentiation potential *in vitro*. Although we find no evidence that *Tppp3^+^Pdgfra^−^* cells turn on *Pdgfra* to become tendon stem cells, we cannot exclude this possibility. Even if they were able to convert to tendon stem cells, their *Pdgfra* gene should be inactivated in R-cKO mice, and the indispensable role of PDGFRα for tenocyte differentiation still stands.

The existence of T-FAPs in tendon stem cell niche has a direct implication to the perennial problem of fibrosis in tendon healing. T-FAPs are the primary contributor to ER-TR7^+^ fibroblasts. T-FAPs and tendon stem cells display similar proliferation kinetics as during regeneration, explaining why fibrosis accompanies tendon healing. Without PDGFRα signalling in tendon stem cells to support tendon regeneration, increased ER-TR7^+^ fibroblasts were observed and reflected a dominance of T-FAPs in this context (see model in [Fig. 7d](#F7){ref-type="fig"}). It is possible that T-FAPs act as a conduit for fibrosis-assisted tendon healing process^[@R6]--[@R10]^. While tenocytes may possess a limited regenerative property^[@R17]^, and if other undefined tendon stem cell populations exist, they are not sufficient to compensate for regeneration.

The dual role of *Pdgfra* in tendon stem cells and T-FAPs highlights the challenge to enhance tendon regeneration while reducing fibrosis via manipulating PDGFRα signalling. Based on labeling efficiencies of our Cre drivers, *Pdgfra* inactivation in stem cells was unlikely complete. We suggest that when functional stem cells are substantially decreased, other subpopulations become dominant to prevent regeneration. Alternatively, *Pdfgra*-inactivated stem cells act in a dominant negative fashion to prevent remaining non-inactivated stem cells from compensation. Thus, the relative ratio among these 3 subpopulations may be critical for regenerative outcome. Co-existence of these subpopulations in Achilles and tail tendons suggests that the same difficulty of regeneration exists across paratenon sheathed tendons; the differences in relative proportions of these subpopulations in these tendons may underlie differences in their regeneration^[@R2],\ [@R19]^. Increased fibrosis by ectopic PDGF-AA confirms this complication and helps explain the variable successes using PDGF-BB to enhance tendon regeneration^[@R48],\ [@R49]^, considering that PDGF-BB can also bind PDGFRβ to stimulates a non-tenogenic response as PDGF-DD. If PDGF signalling is used by other tissue-specific stem cells in the presence of FAP-like cells, fibrosis, either micro-lesions or large scars, during natural tissue regeneration is unavoidable. Collectively, our results frame the conceptual principle to advance the basic understanding of tendon regeneration. The approaches and resources described open the doors to future studies in different tendon types and injury paradigm and should facilitate efforts to create better therapeutic strategies for injured tendons.

Methods {#S13}
=======

Mice {#S14}
----

All animal treatment and care conformed to NIH guidelines and were approved by Institutional Animal Care and Use Committee (IACUC) of the Carnegie Institution for Science (Permit \#A3861-01). Mouse strains were made in-house, from JAX, or from other investigators ([Supplementary Table 2](#SD14){ref-type="supplementary-material"}). Data from mixed-sex groups were used, except that only males were used for scRNA-seq and RNA-seq. The following mouse strains were used at 3 M of age and older:

B6;SJL-Tg(ACTFLPe)9205Dym/J^[@R50]^

C57BL/6J

B6.Cg-Pdgfratm8Sor/EiJ^[@R51]^

B6.129S4-Pdgfratm11(EGFP)Sor/J^[@R40]^

B6.Cg-Gt(ROSA)26Sortm14(CAG-tdTomato)Hze/J^[@R15]^

tg(ScxGFP)^[@R31]^

Tppp3^P2A-iCreERT2-T2A-eGFP^

Tppp3^P2A-ERT2CreERT2^

Generation of *Tppp3* Cre-ER^T2^ alleles {#S15}
----------------------------------------

A BAC clone of C57BL/6 genomic DNA (CHORI) containing *Tppp3* was used to construct homologous recombination plasmids by recombineering^[@R52],\ [@R53]^. A 5' 1.6kb and a 3' 12kb sequences were used as homology arms. The *CG (2A-iCreER^T2^-2A-eGFP)-frt-neo-frt* or the *ECE (2A-ER^T2^-Cre-ER^T2^)-frt-neo-frt* cassette was inserted upstream of the stop codon; *ECE* was described^[@R54]^. No coding or 3'UTR sequences were deleted; information available upon request. The final constructs were in the pWS-tk2 vector^[@R53]^. C57BL/6J;129sv hybrid embryonic stem cells (from Dr. Yixian Zheng) were used. The frt-neo-frt cassette was removed by breeding to Actin-Flp mice^[@R50]^. PCRs using primers amplifying 5' and 3' junctions confirmed homologous recombination. Primers for genotyping and respective product sizes for these alleles are: 5'-CAA CAT TGG CGT CAC CGT AAG TGC CCT G-3'; 5'-ATA GGC ACT GAC TCC CAG ACA GAT GAC A-3'; 5'-TTT GGT GCA CAG TCA GCA GGT TGG ACA T-3' (*Tppp3*^CG^ only); 5'-CCA GGG TTC TCC TCC ACG TCT CCA GCC T-3' (*Tppp3*^ECE^ only). For *Tppp3*^CG^, mutant = 433bp and WT = 549bp. For *Tppp3*^ECE^, mutant = 401bp and WT = 549bp. The following program was used: 95°C for 3', followed by 30 cycles of 95°C 45", 60°C 1', 72°C 1', and final extension 72°C 5' and 12°C hold.

Tamoxifen administration {#S16}
------------------------

Tamoxifen (TMX; Sigma) was prepared as 20 mg/mL stock in corn oil (Sigma) and administered by intraperitoneal (IP) injection at 10 μl/g body weight for 3 consecutive days. After which, mice were chased for 5 d or longer (in legends) before harvest or injury. Similar lineage tracing results were found with 1 M TMX washout.

EdU administration {#S17}
------------------

EdU (0.5 mg/mL in PBS) was administered by IP injection at 10 μl/g body weight as specified in legends and text.

Patellar tendon biopsy punch {#S18}
----------------------------

Mice were anesthetized using 2,2,2-Tribromoethanol dissolved in 2-methyl-2 butanol (Sigma) as 100% (w/v) stock solution, diluted to 2.5% in PBS and used at 20 μl/g body weight. Biopsy punch was as described^[@R11]^ with modifications: \#5 forceps (Dupont) were used to expose the underside of the Patellar tendon. A thin metal sheet was placed underneath the tendon to provide backing for the biopsy punch. An Accu-Sharp Punch MII 0.75 mm diameter (Shoney Scientific) was used. Afterwards, skin was closed using sutures (Ethicon, PERMA-HAND^™^Silk, 5-0, P-3). Mice were placed in a heated chamber to recover. Elizabethan collars were put on the mice for the first 3 days post operation. Knee joints were harvested at specified time points.

PDGF-AA and -DD application {#S19}
---------------------------

Mice were anesthetized as above, and a skin incision was made over the Patellar tendon with surgical scissors. A 1 cm^2^ of 7 mm thickness GelFoam® sponge was flattened with \#5 forceps (Dupont) and positioned over the Patellar tendon. The skin flaps were closed by sutures. For growth factor application, mice were anesthetized with 1.7% Isofluorane (Patterson Veterinary) mixed with oxygen delivered at 1 L/min using an Animal Anesthesia System (VetEquip). Growth factors (in PBS at specified concentrations) or PBS was injected (20 μl) into the sponge. After a week, knee joints were harvested. For cell fate studies, growth factors were used at 5μg/kg body weight.

Patellar tendon sample preparation {#S20}
----------------------------------

Knee joints were dissected out in PBS as described^[@R16]^ with modifications: 7 min fixation with 4% paraformaldehyde (PFA) in PBS on ice, following decalcification, a sucrose infiltration series (10%, 20%, 30% in PBS; overnight each) at 4°C with rocking, and embedded in O.C.T. medium (Tissue-Tek) on dry ice. Twenty μm sagittal sections were collected on Cryofilm Type IIC (Section Lab, Inc., Japan) and affixed to glass slides using 1.5% chitosan in 0.25% acetic acid and allowed to dry at 4°C. Sections throughout the tendon were collected.

Immunofluorescence (IF), EdU, and cell death detection {#S21}
------------------------------------------------------

Sections were hydrated with PBS, permeabilized 15--25' with PBS plus 0.5% Triton X-100 (w/v; 0.5% PBT), rinsed with 0.05% PBT, and blocked overnight with M.O.M. IgG block (Vector Lab). Sections were washed and incubated in blocking solution (10% horse serum, 10% normal goat serum, or 10% donkey serum (pending on secondary antibody host) in 0.05% PBT) for 1.5 h, followed by incubation with primary antibodies diluted in blocking solution overnight at 4°C. Sources and dilutions for primary antibodies are in [Supplementary Table 3](#SD14){ref-type="supplementary-material"}. After several 0.05% PBT washes, fluorescent-conjugated secondary antibodies in blocking solution (1:1000 for Alexa-488, Alexa-568 and at 1:500 for Alexa 647 (Invitrogen)) were applied and incubated at RT for 1 h. Sections were then washed with 0.05% PBT, stained with DAPI (1 μg/mL in 0.05% PBT), and mounted in anti-fade diamond (Invitrogen). *R26R*^tdT^, ScxGFP, and *Pdgfra*^H2B-eGFP^ fluorescence was preserved, thus, no antibody staining was used. For antibodies requiring antigen retrieval (specified in [Supplementary Table 3](#SD14){ref-type="supplementary-material"}), slides were hydrated with PBS, switched to antigen retrieval solution (10 mM sodium citrate, 0.05% Tween-20, pH 6.0 or 10mM Tris buffered saline, 0.05% Tween-20, pH 10.0), incubated for 20 min at 90°C in a hybridization oven, removed, cooled to RT, rinsed with PBS, and proceeded to permeabilization step as above.

EdU detection was performed after permeabilization and prior to M.O.M. IgG block. Click-iT® Alexa Fluor 647 kit (Invitrogen) was used with two modifications: 1) Alexa Fluor-azide was used at half the recommended formulation for 15 min, and 2) 0.5% PBT was used for washes twice after azide, 5 min each.

TUNEL assays (Roche) were used to assess cell death on regenerating samples following the manufacturer's protocol, and no signals were detected.

10X Genomics scRNA-Seq {#S22}
----------------------

For scRNA-seq, a pair of Patellar tendons from a 3 M old male C57BL/6J were dissected and subjected to pre-warmed dissociation solution (3 mg/mL Collagenase I (Worthington) and 4 mg/mL Dispase II (Roche) in PBS)^[@R12],\ [@R55]^ in conical tubes positioned horizontally in a shaking water bath for 45 min at 180 rpm at 37°C. Samples were then lightly triturated with sterilized Pasteur pipettes (VWR), run through a 40 μm filter (VWR) and rinsed with 3 mL TSPC media (αMEM (Gibco) supplemented with 20% EmbryoMax fetal bovine serum ES-cell qualified (EDM Millipore), 100 mM 2-mercaptoethanol, 2 mM GlutaMax, 100 U/mL Penicillin-Streptomycin (Gibco)) to inactivate the enzymes. Cells were centrifuged at 300 x g for 30 min at 4°C. The cell pellet was washed twice with 1 mL PBS and spun for 10 min at 300 x g at 4°C. Cell pellet was resuspended in 0.4% BSA in PBS. Single cell suspension concentration and viability (by Trypan blue exclusion) was confirmed by Countess II Automated Cell Counter (Thermo Fisher Scientific) and hemocytometer (VWR). The digestion time was optimized to yield sufficient number of viable cells. GEMs were made using the Chromium Controller and libraries were made using the Chromium^™^ Single Cell 3' v2 Reagent Kit (10X Genomics). Next-seq (Illumina) was used to obtain at least 157.8K mean reads per cell. 10X genomics analysis software Cell Ranger yielded 4,216 and 1,551 median UMI and genes per cell, respectively, and was used to produce the *t*-SNE graph. By Satija Lab (<http://satijalab.org/howmanycells>) estimate, a metric used to address the accuracy of cell cluster assignment, we reached 99% confidence level for obtaining data from 10 cells of a rare cell type present at 1% of a total population composed of 8 cell types.

Isolation of fluorescently marked tendon cell populations by FACS {#S23}
-----------------------------------------------------------------

Patellar tendons from multiple mice of specified allelic combinations were pooled for cell isolation. The dissociation protocol was adjusted from scRNA-seq procedure to increase cell yield by increasing dissociation time to 1.5 h at 180 rpm at 37°C and triturated until tendon fragments broken up. The washed cell pellet was resuspended in FACS buffer (1% BSA, 1 mM EDTA in PBS). Cells were distinguished by forward and side scatter, and sorting was gated using FITC-A (GFP) and PE-A (tdT) filters to distinguish GFP^+^, tdT^+^, Dual^+^ and negative cell populations ([Extended Data 7](#F15){ref-type="fig"}). Sorting efficacy was confirmed by visualizing live fluorescently positive cell of corresponding population after plating ([Extended Data 2f](#F10){ref-type="fig"}).

RNA-seq {#S24}
-------

Uninjured and regenerated Patellar tendons from *Tppp3*^ECE/+^;*R26R*^tdT^;ScxGFP mice were isolated by FACS, spun down, re-suspended to 1000 cells per subpopulation, and subjected to RNA Direct-zol kit (Zymo), followed by Ovation RNA-seq V2 System (NuGEN) to generate cDNAs. cDNAs were sonicated to 300-500bp (Covaris) and libraries were generated by the TruSeq RNA Library Prep Kit (Illumina) for single-end 150bp reads (Next-seq, Illumina). For uninjured tdT^+^H2B-eGFP^−^ and tdT^+^H2B-eGFP^+^ (from (*Tppp3*^CG/+^;*R26R*^tdT^;*Pdgfra*^H2B-eGFP^mice) subpopulations, mRNA was extracted from 800 intact cells per replicate using the SMART-seq v4 Ultra Low Input Kit (Clontech). Amplified cDNAs were sonicated to 300-500bp (Covaris) and libraries were generated by the ThruPLEX^™^DNA-seq Kit (Rubicon Genomics) for single-end 150bp reads (Next-seq, Illumina). All reads were trimmed to 100bp for comparative purposes. RNA-seq data have been submitted to NCBI GEO (SUB4050561).

Histology {#S25}
---------

For Hematoxylin and Eosin (H&E) staining, cryo-sections were fixed with 95% EtOH, rinsed with tap water, prior to staining using Hematoxylin Gill II, Scott's tap water, and Eosin (all from Surgipath), following manufacturer's protocol. After dehydration with 95% EtOH and 100% EtOH, sections were cleared in Xylene and mounted in Permount (Sigma). For Picrosirius Red staining (Abcam), cryo-sections were first hydrated in tap water then processed according to the manufacturer.

*In vitro* characterization of tendon subpopulations {#S26}
----------------------------------------------------

Patellar tendons from TMX-injected *Tppp3*^CG/+^;*R26R*^tdT^;*Pdgfra*^H2B-eGFP^ mice were used. To increase cell viability, dissociated cells were plated on a 10 cm plate in TSPC media and allowed to recover prior to FACS. Sorted subpopulations were cultured 1) in TSPC media to assay for their fate stability, or 2) in MSC growth media (low glucose DMEM supplemented with 10% MSC qualified FBS, 2mM GlutaMax, 5 μg/mL gentamicin (Gibco)), before subjected to multipotential differentiation assays.

1\) For cell fate stability, all subpopulations were seeded in TSPC media with daily media change:

### H2B-eGFP^+^tdT^+^ tendon stem cells: {#S27}

Cells were fixed at 24 h, 72 h and 120 h with 2% PFA and stored at 4°C in PBS. Immunofluorescence for GFP and tdT was used to determine the cell fractions expressing these markers. Additional wells at 120 h were stained with anti-TPPP3 or with anti-PDGFRα to confirm endogenous protein expression.

### H2B-eGFP^+^tdT^−^ T-FAPs: {#S28}

Media were supplemented with PBS (control) or 10 μM 4-hydroxytamoxifen for 24 h intervals: 0-24 h, 48-72 h, and 96-120 h to assess tdT expression. Immunofluorescence for GFP and tdT were applied to samples of these time points; anti-TPPP3 were used to confirm negative expression of endogenous TPPP3 ([Extended Data 6b](#F14){ref-type="fig"}). The concentration and duration of 4-hydroxytamoxifen were determined to be efficient for inducing tdT expression.

### tdT^+^H2B-eGFP^−^ cells: {#S29}

Live images were taken every 24 h until 96 h to assess tdT and H2B-eGFP signals. Anti-TPPP3 antibodies were used to determine the maintenance of endogenous TPPP3 expression ([Extended Data 6b](#F14){ref-type="fig"}).

Tile scan images of each well were captured on the Leica TCS SP8 and the conversion index was calculated using automated filtering and thresholding in Imaris (Bitplane).

2\) For multipotential differentiation assays, each sub-population was subjected to culturing and differentiation conditions per murine MSCs^[@R12]^. Murine MSCs (Invitrogen) were used as a positive control in parallel. For adipogenesis and chondrogenesis, cells were expanded in MSC growth media. For osteogenesis, cells were expanded in osteogenic growth media (αMEM, 20% MSC qualified FBS, 2 mM GlutaMax, 100 U/mL Penicillin-Streptomycin (Gibco), 10 nM Dexamethasone (Sigma)). At 80% confluency, cells were trypsinized, pelleted and seeded for assay.

#### Adipogenesis: {#S30}

Cells were incubated for 24 h in MSC growth media before switched to Adipogenic Differentiation Media (Gibco StemPro^™^Adipogenesis Differentiation Kit, Life Technologies). At d 14, cells were stained with Oil Red O. Non-differentiation control was maintained in MSC growth media.

#### Chondrogenesis: {#S31}

Cells were incubated for 24 h in MSC growth media before switched to Chondrogenic Differentiation Media (Gibco StemPro^™^Chondrogenic Differentiation Kit, Life Technologies). At d16, cells were stained with Safranin O or Alcian Blue pH 1. Non-differentiation control was maintained in MSC growth media.

#### Osteogenesis: {#S32}

Cells were grown to confluency in osteogenic growth media before switched to osteogenic induction media (αMEM, 20% MSC qualified FBS, 2mM GlutaMax, 100 U/mL Penicillin-Streptomycin, 200 ng/mL BMP2 (Gibco), 10nM Dexamethasone, 100μM Ascorbic acid 2-phosphate sesquimagnesium (Sigma), 2mM β-Glycerophosphate (EDM Millipore). After 21 d, cells were stained with 2% Alizarin Red S pH 4.2 (Sigma).

Transmission electron microscopy (TEM) sample preparation and analyses {#S33}
----------------------------------------------------------------------

Patellar tendons were isolated at 30 dpi from *Tppp3*^CG/+^;*R26R*^tdT^;*Pdgfra*^+/+^ (Control Injured, CI) and *Tppp3*^CG/+^;*R26R*^tdT^;*Pdgfra*^fl/fl^ (conditional Knockout Injured, cKO I) mice. *Tppp3*^CG/+^;*R26R*^tdT^;*Pdgfra*^+/+^ tendons were used for control uninjured (CU). Knee joints were isolated and fixed as described^[@R17],\ [@R56]^ with modifications: 1) fixative in 0.05M phosphate buffer pH 7.4 in lieu of Dulbecco's serum-free media, 2) rinses with PBS, 3) post-fixation with 1% OsO~4~ + 1% KFeCN in PBS followed by H~2~O rinse, 0.05M Maleate pH 6.5, 0.5% UAc in Maleate, and 4) samples were polymerized for 5 d. TEM images of transverse sections were collected at several magnifications for evaluation. Collagen fibril diameters were measured using Fiji; 6 representative images were analyzed for each tendon (n= 4 per group) and a total of 1000 fibrils analyzed per sample except for cKO I samples, 150 fibrils at the edge of the hole. Cross-sections were taken from the central third (location of biopsy punch) of the Patellar tendon.

Confocal Imaging {#S34}
----------------

Tile scan images were captured using a Leica TCS SP8 X equipped with a Leica 40X/1.30 objective using Leica LAS-X software. The entire tendon section was imaged at 1 μm z-steps. Imaris (Bitplane) was used for 3D reconstruction, surface rendering and automated cell counting. Average length and thickness of P90 Patellar tendon sagittal section is 3,250 μm and 300 μm, respectively. Injury domain/area was defined by EdU boundary or tdT boundary within midsubstance.

Whole Mount Multiphoton Imaging {#S35}
-------------------------------

Isolated Patellar tendons were fixed in 10% neutral, buffered formalin (Sigma) at room temperature 30-60' nutating, washed over 1 h with PBS, mounted in 1.2% low melt agarose (SeaPlaque) in PBS onto Fluorodish glass bottom dish (World Precision Instruments, Inc., FD35-100) and flattened by a 12 mm round cover glass (Fisher Scientific). Optical sections were captured at 1 μm steps to a total depth of 100-150 μm using an inverted Leica TCS SP5 II, equipped with a Leica 25x/0.95 water objective and Chameleon Vision Laser (Coherent) tuned to 925 nm. SHG, ScxGFP, and tdT signals were captured using external detection filters at the ranges of 430-480 nm, 500-550 nm, and 565-605 nm, respectively. For these image acquisitions, Leica LAS software was used.

Light and Polarized Light Imaging {#S36}
---------------------------------

Images of histological sections were taken on a Nikon Eclipse E800 scope with Plan Fluor Apo objectives (magnification/numerical aperture: 4x/0.13, 10x/0.45, 20x/0.75). For picrosirius red, a polarizer was used at 90° relative to incident light. Images for adipogenesis and osteogenesis were taken on a Zeiss Axiovert25 scope equipped with 20x/0.3 phase objective. Images for chondrogenesis were taken on a Zeiss Stemi SV 11 Apo scope equipped with a S1.0x objective. For these image acquisitions, Canon EOS Rebel T3i cameras and EOS Utility software were used.

Code availability {#S37}
-----------------

Programming code for RNA-seq analysis has been deposited to GitHub (<https://github.com/ciwemb/fan-2019-tendon>).

Statistics and reproducibility {#S38}
------------------------------

Data are represented as the mean ± SEM (error bars) of 3--5 biological replicates, except for uninjured and regenerated RNA-seq data (2 technical replicates from 14 tendons; each n represents a pooled average) and uninjured tdT^+^H2B-eGFP- and tdT^+^H2B-eGFP^+^ RNA-seq data (3 technical replicates from 24 tendons; each n represents a pooled average). Statistical analyses were performed using Excel or GraphPad Prism 7 by unpaired two-tailed Student *t*-test, Chi-squared test, two-way *ANOVA*, Ingenuity Pathway Analysis (Qiagen), Cufflinks package^[@R57]^, DESeq package^[@R58]^, (Loupe Cell Browser/Cell Ranger (10X Genomics), Seurat package^[@R59]^, and Monocle 2 package^[@R39]^ (stipulated in legends). For the unpaired two-tail Student's *t*-test, specific values are labeled on plots or appear in legends. For the Chi-square test, \#\# *P* \< 0.01, non-significant equals *P* \> 0.05. For RNA-seq, False Discovery Rate adjusted q-value \< 0.05 determined by RNA-seq analysis package (*Cufflinks* or *DESeq* as specified) was considered significant. All data were included in the statistical analyses.

Data availability {#S39}
-----------------

RNA--seq and scRNA-seq data that support the findings of this study have been deposited at NCBI under accession code SUB4050561. Previously published sequencing data that were re-analysed here are available under accession code GSE89663. All other data supporting the finds of this study are available from the corresponding author upon reasonable request.

Extended Data {#S40}
=============

![*Tppp3*^CG^ driver is TMX dependent.\
**a**, Cells expressing ≥1 UMI of *Acta2* from ([Fig. 1a](#F1){ref-type="fig"}). **b**, Cartoon summary (right) from cell atlas ([Fig. 1a](#F1){ref-type="fig"}) and immunofluorescence ([Fig. 1b](#F1){ref-type="fig"}); midsubstance (maroon), sheath (gray), and key (left). **c**, Fluorescence images of *Tppp3*^CG/+^;*R26R*^tdT^ tendon; upper, no TMX control with anti-GFP antibody (Ab.); middle, +TMX and Ab.; lower, +TMX and no Ab. control--eGFP expressed by the *Tppp3*^CG^ driver is only detectable with Ab. staining; n=3. *Tppp3*^CG^ driver labels 38.3±2.6 (Mean±SEM)% of sheath cells. **d**, *Tppp3*^CG^ driver labeling efficiency is 79.5±3.4 (Mean±SEM)%; n=3 animals; N=9 samples/n. **e**, Fluorescent images of *Tppp3*^CG/+^;*R26R*^tdT^ tendons: digit flexor (leftmost), tail (left), Achilles (right) or Patellar (rightmost); TMX pulsed at embryonic day (E)15.5 and chased to E17.5; Col I, collagen-I antibody stained; dashed line, midsubstance-sheath boundary; n=3 animals/tendon. **f**, Fluorescent images of *Tppp3*^CG/+^;*R26R*^tdT^ Patellar tendon; TMX pulsed at postnatal day (P)5 and chased to P8; dashed line, midsubstance-sheath boundary; n=3 animals. **g**, Sheath cell fractions (key; right) over time; n=3 animals/time point; N=3 samples/n; all ns; mean for (Negative, eGFP^+^, tdT^+^, and eGFP^+^tdT^+^) at specified time: (P8; 0.636, 0.104, 0, 0.260), (P30; 0.627, 0.104, 0, 0.269), (P90; 0.602, 0.089, 0, 0.308). **h**, Midsubstance cell fractions (key same as **g**) over time; n=3 animals/time point; N=3 samples/n; all ns; mean for (Negative, eGFP^+^, tdT^+^, and eGFP^+^tdT^+^) at specified time: (P8; 0.994, 0, 0, 0.006), (P30; 0.991, 0, 0.001, 0.008), (P90; 0.984, 0, 0.001, 0.015). **i**, Midsubstance cell fractions (key; right) over time; n=3 animals/time point; N=9 samples/n; all non-significant by Chi-square test; mean for (Negative, eGFP^+^, tdT^+^, and eGFP^+^tdT^+^) at specified time: (5d; 0.961, 0.004, 0, 0.035), (3M; 0.849, 0.003, 0, 0.148), (6M; 0.929, 0, 0, 0.071), (10M; 0.920, 0.009, 0, 0.071). **j**, Wholemount multiphoton images of uninjured and biopsy punched (immediately after (T0)) Patellar tendon; n=3; collagen fibers visualized by second harmonic generation (SHG). **k**, Regenerated tendon immuno-stained for Tenascin-C (TNC); asterisks, proliferated *Tppp3*-lineage cells in TNC matrix of midsubstance; \^, self-renewed *Tppp3*-lineage in sheath with lower TNC signal; n=3. (**l**, **m**) Zoomed in FMOD images from [Fig. 1g](#F1){ref-type="fig"}; n=3 independent repeats; asterisks, proliferated *Tppp3*-lineage in midsubstance (**l**); \^, self-renewed *Tppp3*-lineage in sheath (**m**). Scale bar = 30 (**c**), 15 (flexor) 50 (tail, Achilles, Patellar) (**e**), 40 (**f**), 200 (**j**), 50 (**k**), 10 (**l**, **m**) μm. Error bars = SEM (**g**, **h**, **i**). Two-tailed Student's *t*-test (**g**, **h**).](nihms-1540808-f0009){#F9}

![*Tppp3*^ECE^ and ScxGFP allow for compartmental molecular characterization.\
**a**, *Tppp3*^ECE/+^;*R26R*^tdT^;ScxGFP tendon showed TMX-dependent cell marking (tdT^+^) in sheath; n=3. Given the proportion of labeled sheath cells (22.7 ± 3.7 (Mean±SEM) %) relative to *Tppp3*^CG^, *Tppp3*^ECE^ driver labeling efficiency is \~60%; dashed line, midsubstance-sheath boundary. ScxGFP signal was detected without antibody--not every midsubstance cell is ScxGFP^+^. **b**, Fractions of sheath tdT^+^ScxGFP^+^ cells at given dpi; n=3 animals/time point, N=3 samples/n; mean per time-point (3d, 7d, 14d, 21d, 28d) as follows: (0.034, 0.262, 0.062, 0.035, 0.058). **c**, Midsubstance images at specified regeneration windows related to [Fig. 2b](#F2){ref-type="fig"}, n=3 independent repeats. **d**, Bar graph (top) for average number of midsubstance tdT^+^ cells at specified time point; mean at specified time-point (3d, 7d, 14d, 21d, 28d): (74.9, 148, 367.6, 387.1, 326.7). Line graph (bottom) for % of proliferated (EdU^+^) midsubstance *Tppp3*-lineage marked and ScxGFP^+^ cells (keys, upper right); n=3 animals/time point, N=3 samples/n; comparisons for a, tdT^+^ScxGFP^−^ vs tdT^+^ScxGFP^+^, b, tdT^+^ScxGFP^−^ vs tdT^−^ScxGFP^+^, c, tdT^+^ScxGFP^+^ vs tdT^−^ScxGFP^+^ at 28 d; all other time comparisons not-significant. **e**, Regeneration assay for 30 d with daily EdU throughout; n=3 animals/condition, N=3 samples/n: asterisks, tdT^+^ScxGFP^+^EdU^+^ cells in midsubstance; \<, tdT^+^EdU^+^ cells in sheath. Below, quantified sheath and midsubstance cell fractions (key; right) in uninjured (U) and injured (I) conditions; Chi-squared test \#\# *P* \< 0.01. *t*-test, in parentheses following specified cell fraction in paired order of Sheath Uninjured-Sheath Injured and Midsubstance Uninjured-Midsubstance Injured: Negative (*P*=0.0077, *P*=0.299), ScxGFP^+^ (*P*=0.332, *P*=3.63E-07), tdT^+^ (*P*=0.0022, *P*=8.32E-08), tdT^+^ScxGFP^+^ (*P*=0.068, *P*=3.06E-08). Mean for (Negative, ScxGFP^+^, tdT^+^, and tdT^+^ScxGFP^+^) fractions for specified condition as follows: (Sheath U; 0.723, 0, 0.277, 0), (Sheath I; 0.751, 0.001, 0.242, 0.006), (Midsubstance U; 0.145, 0.854, 0, 0.001), (Midsubstance I; 0.188, 0.485, 0.143, 0.184). **f**, Fluorescent images of FACS isolated cells from 30 d regenerated *Tppp3*^ECE/+^;*R26R*^tdT^;ScxGFP tendons related to [Fig. 2c](#F2){ref-type="fig"}, n=3 independent repeats. **g**, Averaged, normalized log10 counts from DESeq comparison between tdT^+^ScxGFP^+^ and tdT^−^ScxGFPr^+^ cells: arranged in boxes by transcription factors (blue), collagens (green), and proteoglycans/glycoproteins (magenta); q-value \< 0.05 (\*). **h**, Table for selected gene categories: log2(fold-change) directionality of enrichment in tdT^+^ScxGFP^+^r (yellow) versus uninjured tdT^+^ (red) cells; n=2 samples. Unpaired two-tail Student's *t*-test (**b**, **d**, **e**); error bars = SEM (**b**, **d**, **e**); scale bars= 30 (**a**, **c**), 50 (**e**, **f**) μm.](nihms-1540808-f0010){#F10}

![Novel sub-compartmental markers, pathway analysis, and additional pseudotime trajectories.\
**a**, Immunofluorescence of novel sheath markers (LAMININ for *Lama4*; SCA-1 for *Ly6a/e*; PLIN for *Plin2*) identified in [Fig. 3b](#F3){ref-type="fig"}; dashed line, midsubstance-sheath boundary; n=3 independent repeats; scale bar = 50 μm. **b**, Table for genes in selected matrix categories from [Fig. 3a](#F3){ref-type="fig"}; same organization as for [Fig. 3b](#F3){ref-type="fig"}, n=2 replicates. **c**, Table for differentially expressed signaling pathway genes from [Fig. 3a](#F3){ref-type="fig"}, n=2 replicates. **d**, Canonical Pathways list generated by Ingenuity Pathway Analysis^®^ (IPA) on DE analysis gene list filtered by q-value \< 0.05; positive z-score (orange) indicates predicted activation; PDGF signaling (red boxed) and its downstream effector branches ERK/MAPK and PI3K/AKT are enriched (indicated by asterisks), n=2 replicates. **e**, Relative expression of genes (as indicated) plotted in pseudotime, colored by state, and with expression level trend (line), related to [Fig 3d](#F3){ref-type="fig"}.](nihms-1540808-f0011){#F11}

![*Tppp3*^+^*Pdgfra*^+^ sub-population has tenogenic propensity.\
**a**, Novel Sheath markers: Log~10~ gene expression level specified per individual cell plotted in pseudotime trajectory of cluster 2 and 4 cells. Red circles (enrichment in state 1), correlating with *Tppp3* and *Pdgfra* ([Fig. 3d](#F3){ref-type="fig"}), suggesting a unique role for state 1-*Tppp3*^+^*Pdgfra*^+^ cells (see [Fig. 3d](#F3){ref-type="fig"}). **b**, Fluorescent images of *Tppp3*^ECE/+^;*R26R*^tdT^;*Pdgfra*^H2B-eGFP^ tendon 5 d after TMX-induced marking; n=3; dashed line, midsubstance-sheath boundary; yellow arrowheads, tdT^+^H2B-eGFP^+^ cells; red arrowheads, tdT^+^H2B-eGFP^−^; green arrowheads, tdT^−^H2B-eGFP^+^; blue arrowheads, negative; direct fluorescent imaging to visualize GFP signal from *Pdgfra*^H2B-eGFP^. **c**, Relative cell fractions (keys; bottom) within Tppp3^+^(tdT^+^) population (bar graph) and within the sheath (pie chart) from data in (**b**); n=3 animals, N=3 samples/n; mean(%)=(tdT^+^H2B-eGFP^+^, 59.1; tdT^+^H2B-eGFP^−^, 40.9). **d**, (Left) Fluorescent images of *Tppp3*^CG/+^;*R26R*^tdT^;*Pdgfra*^H2B-eGFP^ Achilles or tail tendon 5 d after TMX-induced marking; n=3 animals; dashed line, midsubstance-sheath boundary; arrowheads same code as **b**; direct fluorescent imaging to visualize GFP signal from *Pdgfra*^H2B-eGFP^. (Right) Bar graph of fraction of sheath cell populations across respective tendon types; A, Achilles; P, Patellar; T, tail; circles represent individual n; mean per specified population (Negative, tdT^+^H2B-eGFP^−^, tdT^+^H2B-eGFP^+^, tdT^−^H2B-eGFP^+^) in tendon type (A; 0.242, 0.134, 0.175, 0.448), (P; 0.428, 0.144, 0.229, 0.199), (T; 0.442, 0.047, 0.143, 0.368). **e**, Stem cell (Tppp3^+^PDGFRα^+^) recombination efficiency per Tppp3 driver; *Tppp3*^CG^ efficiency is 77.0±1.6 (Mean±SEM)% and *Tppp3*^ECE^ efficiency is 56.1±2.9 (Mean±SEM)%; determined in situ by tdT^+^ co-localization with anti-TPPP3 antibody^+^PDGFRa^H2BeGFP+^ cells; circles represent n; n=4 samples. **f**, Bar graph of proliferation indices from entrant populations corresponding to [Fig. 4f](#F4){ref-type="fig"}, all comparisons non-significant; circles indicate n; n=3 animals, N=3 samples/n; mean (%) per population (tdT^+^Pdgfra^−^, 43.0 ; tdT^+^Pdgfra^+^, 51.8; tdT^−^Pdgfra^+^, 42.0). **g**, Fluorescent images of midsubstance with specified treatment on *Tppp3*^ECE/+^;*R26R*^tdT^;ScxGFP tendon; n=3 independent repeats. Error bars = SEM (**c**, **d**, **e**, **f**); scale bar = 30 (**d**, **g**), 50 (**b**) μm; two-tailed Student's *t*-test (**d**, **f**).](nihms-1540808-f0012){#F12}

![PDGFRα signaling is required for regeneration but not for homeostasis.\
**a**, Immunofluorescence for indicated sheath markers on *Tppp3*^CG/+^;*Pdgfra*^fl/fl^ tendon with same experimental scheme as ([Fig. 6c](#F6){ref-type="fig"}) except for without punch and EdU; n=3; dashed line, midsubstance-sheath boundary. **b**, Experimental scheme and fluorescent images of R-control, *Tppp3*^CG/+^;*R26R*^tdT^, and R-cKO, *Tppp3*^CG/+^;*R26R*^tdT^;*Pdgfra*^fl/fl^; chased 30 d after TMX; n=3-4/condition; EdU daily throughout; dashed line, midsubstance-sheath boundary; asterisk, tdT^+^EdU^+^ cell. **c**, Fluorescent images of Rcontrol and R-cKO of sheath compartment in regenerate area; harvested at 14 dpi and EdU daily throughout; n=3 (R-control), 4 (R-cKO) animals/condition; dashed line, midsubstance-sheath boundary; arrowheads, eGFP^−^tdT^+^ cells. Stacked column for the distribution (in %) of various cell populations (keys at side); mean (%) for specified population (Negative, eGFP^+^, tdT^+^, eGFP^+^tdT^+^) as follows: (R-control; 48.3, 8.0, 2.2, 41.5), (R-cKO; 53.0, 15.1, 10.6, 21.2). Bar graph for average number of sheath cells per injury area; mean = (R-control, 1013; R-cKO, 667). **d**, Controls for SCX immunofluorescence; anti-SCX antibody reacts strongly to midsubstance cells (arrowheads); n=3 independent repeats. **e**, Fluorescent micrographs of ScxGFP tissue stained with anti-SCX antibody, 93.6±1.9 (mean±SEM) % of ScxGFP^+^ cells are anti-SCX^+^; n=3 independent repeats; dashed line, midsubstance-sheath boundary; arrowheads, anti-SCX^+^ScxGFP^+^ cells. **f**, Stacked columns for the distribution (in %) of various cell populations (keys at side); n=3 animals; mean (%) per population (tdT^−^, tdT^+^) as indicated: R-control (16.7, 16.8), R-cKO (32.7, 13.8). Unpaired two-tail Student's *t*-test (**c, f**); error bars = SEM (**c, f**); scale bar = 20 (**d, e**), 30 (**b**), 50 (**a, c**) μm.](nihms-1540808-f0013){#F13}

![Sheath subpopulations exhibit little conversion *in vitro*.\
**a**, Fluorescent micrographs of purified tdT^+^H2B-eGFP^+^ cultured for 24 h in TSPC conditions stained with anti-PDGFRα or anti-TPPP3. **b**, Fluorescent micrographs of anti-TPPP3 antibody validation on cultured sub-populations. n=3 independent repeats (**a**, **b**). Scale bars = 100 (**b**), 200 (**a**) μm.](nihms-1540808-f0014){#F14}

![Example of FACS gating strategy\
Cells were selected in FSC/SSC dot plot to remove debris; single cells were gated using the FSC-H/FSC-W dot plot. GFP^+^ (FITC-A), tdT^+^ (PE-A) cells were gated and compared with a control sample without tamoxifen induction or carrying ScxGFP. Tomato^+^-only cells were gated from tomato^+^GFP^+^ cells by population segregation.](nihms-1540808-f0015){#F15}
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Supplementary Table 1

Differentially expressed genes per cell cluster from scRNA-seq data (see [Fig.1a](#F1){ref-type="fig"}, n = 2,451 cells) derived from Loupe Cell Browser using *CellRanger* clustering and statistical ranking. Average, normalized UMI counts per each gene ID (with corresponding color code in [Fig.1a](#F1){ref-type="fig"}) listed as well as cluster log2fold enrichment value, cluster assignment number and cell type identity.

Supplementary Table 2

Mouse alleles used in this study with abbreviated name as appears in the manuscript as well as full name. Allele supplier indicated as well as stock number and citation (where applicable).

Supplementary Table 3

Primary antibodies used in this study with dilution factors and special conditions for antigen retrieval indicated.
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![Tendon harbors a self-renewing stem cell population.\
**a**, *t*SNE plot for 2491 cells. Unsupervised clustering by Cell Ranger: keys to the clustering number to the right and cell type assignments on the plot. **b**, Immunofluorescence for indicated markers. Dashed lines indicate midsubstance-sheath boundary. **c**, Diagrams for *Tppp3*^CG^ driver and experimental regimen: at P90, cells were marked by TMX for 3 d and chased to 5 d, and 3, 6, 10 M. **d**, Immunofluorescence images at 5 d and 10 M, and quantified cell fractions (keys at bottom); dashed line, midsubstance-sheath boundary; n=3 animals/condition; all ns by Chi-Square test; mean for (Negative, eGFP^+^, tdT^+^, and eGFP^+^tdT^+^) at specified time as follows: (5 d; 0.436, 0.113, 0, 0.451), (3 M; 0.410, 0.104, 0.0002, 0.104), (6 M; 0.479, 0.070, 0, 0.451), (10 M; 0.479, 0.057, 0, 0.465). **e**, Schema for tendon regeneration assay: same cell marking regimen as in (**c**), punch injury 5 d later and chased to 30 d; daily EdU for first 15 d. **f**, Diagram (left) of Patellar tendon at sagittal plane: P, patella; F, femur; T, tibia; midsubstance in white; sheath in gray; site of punch, red cylinder; imaged area, dashed box. Images in the middle and quantification to the right: U, uninjured; I, injured; examined cell groups same as (**d**); Chi-square test, \#\# p \< 0.01; n=3 animals/condition; mean for (Negative, eGFP^+^, tdT^+^, and eGFP^+^tdT^+^) for specified condition as follows: (Sheath U; 0.608, 0, 0.051, 0.341), (Sheath I; 0.513, 0.015, 0.048, 0.424), (Midsubstance U; 1, 0, 0, 0), (Midsubstance I; 0.542, 0, 0.420, 0.038). **g**, High magnification of FMOD staining of 30 d regenerated tendons: \*, proliferated *Tppp3*-descendant; \^, self-renewed *Tppp3* lineage in sheath; 3 independent repeats; also see [Extended Data 1k](#F9){ref-type="fig"}--[m](#F9){ref-type="fig"}. Scale bars = 30 (**a**), 50 (**d**, **f**, **g**) μm.](nihms-1540808-f0001){#F1}

![*Tppp3* stem cells amplify early and generate tenocytes by second week.\
Diagrams for experimental design (**a**), and time course (**b**); daily EdU staggered in time windows (dashed line with arrow in **b**). Left bottom panels in (**a**) are whole mount 100 μm maximal projections at specified times in transverse views (except for 14 d, longitudinal view); 3-4 independent repeats: yellow arrows, tdT^+^ScxGFP^+^ cells; asterisks, tdT^+^ScxGFP^−^ sheath cells; white arrows, entrant tdT^+^ScxGFP^−^; green arrows, entrant ScxGFP^+^ cells; dashed line, injury boundary; bracket, ScxGFP^+^ cells in SHG^+^ domain. Right bottom panels: cartoon summaries, axes indicated. Mid-panels in (**b**) are selected images at 7 d and 28 d; dashed lines, midsubstance-sheath boundary; n=3 animals/time point. Bottom left: line graph for % of EdU^+^ cells in specified population. Mean (%) per time stated for tdT^+^ScxGFP^+^ and tdT^+^ScxGFP^−^. Bottom right: bar graph for the % of specified lineage in the total labeled population in the sheath; two-way *ANOVA* for interaction, *df* = 4, *P* = 7.602E-20; each population is also subjected to unpaired Student's *t*-test in parentheses following specified lineage fraction in paired order of indicated time points for tdT^+^ScxGFP^−^ and tdT^+^ScxGFP^+^ (n=3 animals). Error bars = SEM. **c**, Schema for FACS isolation of marked cell population: sorted by FITC-A for tdT^−^ScxGFP~r~^+^ (tenocytes in regeneration environment) and by PE-A for tdT~r~^+^ScxGFP^−^ (renewed *Tppp3* lineage); tdT~r~^+^ScxGFP~r~^−^ and tdT^+^ScxGFP~r~^+^ populations gated by population separation. **d**, Venn diagram from DESeq comparison between tdT^+^ScxGFP~r~^+^ and tdT~r~^−^ScxGFP~r~ cells: \# of transcripts labeled; 94.9% transcripts not differentially enriched (overlap region, q-value \> 0.05 for cutoff). **e**, Averaged, normalized log~10~ counts of selected canonical tendon genes of the overlapped group in (**d**): blue box for transcription factors, green for collagens, and magenta for proteoglycans/glycoproteins. **f**, Venn diagram from DESeq comparison between tdT^+^ScxGFP^−^~r~ and tdT (quiescent *Tppp3* cells): \# of transcripts labeled; transcripts not differentially enriched (overlap region, q-value \> 0.05 for cutoff); boxed genes represent genes found in overlap, sheath markers in red. Scale bars = 50 μm (**a**), 100 μm (**b**). Statistical analysis provided in source data for Figure 2.](nihms-1540808-f0002){#F2}

![Molecular characterization of tendon sub-populations.\
**a**, Numbers of up-regulated genes by *Cufflinks* in uninjured FACS-isolated *Tppp3*^+^ (tdT^+^ScxGFP^−^) and tenocyte (tdT^−^ScxGFP^+^) cells (duplicate); 5 FPKM cutoff in at least one population; false discovery rate (FDR) adjusted q-value \< 0.05. **b**, Table for selected gene categories: log2(fold-change) directionality of enrichment in ScxGFP^+^ (green) versus *Tppp3*^+^ (red) cells (**a**): gene ID is followed by scRNA-seq cluster assignment in parentheses; n=2 replicates, pooled from 14 tendons; FDR adjusted q-values by *Cufflinks* package are shown. **c**, Table for number and % of cluster 2 cells in total, expressing *Tppp3,* and expressing both *Tppp3* and *Pdgfra*; 1 UMI for cutoff. **d**, Top panel: Pseudotime trajectory of cluster 2 and 4 cells from scRNA-seq ([Fig. 1a](#F1){ref-type="fig"}) re-plotted using top 1,000 genes by smallest q-value for ordering. Three *Tppp3*^+^ states were delineated with state 1 enriched for *Pdgfra*; keys to cell states at the top. Log~10~ expression level of *Tppp3* (middle) and *Pdgfra* (bottom) per individual cell plotted in pseudotime trajectory of cluster 2 and 4 cells from scRNA-seq; their enrichment in state 1 is noted by red circles. **e**, Images of *Tppp3*^CG/+^;*R26R*^tdT^;*Pdgfra*^H2B-eGFP^ tendon, Images representative of 3 samples. TMX for 3 d and harvested 5 d later; dashed line, midsubstance-sheath boundary; yellow arrowheads, tdT^+^ H2B-eGFP^+^ cells; red arrowheads, tdT^+^H2B-eGFP^−^; green arrowheads, tdT^−^H2B-eGFP^+^; blue arrowheads, negative; direct fluorescent imaging to visualize GFP signal from *Pdgfra*^H2B-eGFP^ but not eGFP from *Tppp3*^CG^ allele requiring antibody; scale bar = 30 μm. **f**, Relative cell fractions (keys at bottom) within Tppp3^+^(tdT^+^) population (left bar graph; mean (%) (tdT^+^H2B-eGFP^+^, 61.4), (tdT^+^H2B-eGFP^−^, 38.6)) and within the sheath (right pie chart) from (**e**); n=3 animals. SEM = error bars or labeled.](nihms-1540808-f0003){#F3}

![*Tppp3*^+^*Pdgfra*^+^ cell gene signature and contribution during regeneration.\
**a**, PCA plot from RNA-seq data of tdT^+^Pdgfra^−^ (tdT^+^H2B-eGFP^−^~1-3~) and tdT^+^Pdgfra^+^ (tdT^+^H2B-eGFP^+^~1-3~) tendon cells from *Tppp3*^CG/+^;*R26R*^tdT^;*Pdgfra*^H2B-eGFP^ tendons; 3 samples. **b**, Heatmap of state 1 (from [Fig. 3d](#F3){ref-type="fig"})-enriched ordering genes (586 genes) used to generate pseudotime trajectory using tdT^+^Pdgfra^−^ (tdT^+^H2B-eGFP^−^~1-3~) and tdT^+^Pdgfra^+^ (tdT^+^H2B-eGFP^+^~1-3~) cells (from **a**). **c**, Heatmap of top 1000 genes from triplicate RNA-seq of tdT^+^Pdgfra^−^ (tdT^+^H2B-eGFP^−^~1-3~) and tdT^+^Pdgfra^+^ (tdT^+^H2B-eGFP^+^~1-3~) tendon cells with the genotype in (**a**); 47% of tdT^+^Pdgfra^+^ and 0.4% tdT^+^Pdgfra^−^ expressed genes overlap with top 500 FAP genes (GSE89633). **d**, Heatmap of canonical tendon markers from (**b**); asterisks, transcription factors; \<, collagens; *Pdgfra* and *Tppp3* (red boxes); *Scx* (green box). **e**, Heatmap of midsubstance markers in quiescent tenocyte (ScxGFP~1-2~) and tdT^+^Pdgfra^+^ (tdT^+^H2B-eGFP^+^~1-3~) cells. **f**, 30 dpi of *Tppp3*^ECE/+^;*R26R*^tdT^;*Pdgfra*^H2B-eGFP^ tendon; EdU daily for the first 15 d; yellow arrowheads, tdT^+^H2B-eGFP^+^; red arrowhead, tdT^+^H2B-eGFP^−^; green arrowheads, tdT^−^H2B-eGFP^+^; dashed line, midsubstance-sheath boundary; n=3 animals; bar graph for the fraction of midsubstance tdT population that is PDGFRα^+^, mean=86.2%. **g**, 14 dpi of *Tppp3*^CG/+^;*R26R*^tdT^ tendon; 3 samples; upper panels, uninjured area; lower panels, injured area; blue arrowheads, ER-TR7^+^-only; red arrowheads, ER-TR7^−^tdT^+^; dashed lined, midsubstance-sheath boundary. **h**, 30 dpi of *Tppp3*^ECE/+^;*R26R*^tdT^;*Pdgfra*^H2B-eGFP^ tendon; 3 samples; green arrowheads, ER-TR7^+^tdT^−^H2B-eGFP^+^; yellow arrowhead, ER-TR7^+^tdT^+^H2B-eGFP^+^; dashed line, midsubstance-sheath boundary. **i**, Pie chart distribution of ER-TR7^+^ cells in injury area from **h**; n=3; key to the right. Error bars = SEM (**f**, **i**); scale bars = 20 (**f**, **h**), 40 (**g**) μm.](nihms-1540808-f0004){#F4}

![PDGF-AA drives *Tppp3*-lineage towards tenogenesis.\
**a**, Diagram for PDGF-AA (AA), PDGF-DD (DD) and PBS treatment to tendon sheath via GelFoam (orange line); arrow, treatment site; blue 'D' and magenta 'E' boxes, sheath and midsubstance regions, respectively, for quantification in (**d**) and (**e**). **b**, Experimental scheme for (**a**): annotation same as previous schemes, plus GelFoam implant and protein treatment (solid line with arrow). **c**, Bar graph for fraction of sheath cells proliferated with two PDGF-AA concentrations using wildtype C57BL/6J mice; n=2 (0.5ug/kg) or n=3 (No Gelfoam, PBS, 5ug/kg) animals/condition; 15 samples/condition; No GelFoam and PBS, controls. **d**, Fluorescent images of sheath compartment with specified treatment on *Tppp3*^ECE/+^;*R26R*^tdT^;ScxGFP tendon; bar graph (upper right) for % of *Tppp3*-lineage proliferated in sheath per treatment; n=3 animals/condition; with 2 (PBS) or 3 (AA, DD) samples/condition. Percentages of various tdT^+^-lineage fractions (keys at bottom) in sheath (lower right): Distribution comparisons between PBS-AA, PBS-DD, and AA-DD pairs by Chi-square tests, all \#\# *P* \< 0.01. Each cell fraction is also subjected to Student's *t*-test in parentheses following specified cell fractions in paired order of (PBS-AA, PBS-DD, and AA-DD): tdT^+^ (*P*=1.01E-05, *P*=1.51E-02, *P*=1.1E-03), tdT^+^EdU^+^ (*P*=0.264, *P*=0.021, *P*=0.233), tdT^+^ScxGFP^+^ (*P*=5.26E-03, *P*=0.161, *P*=2.73E-03), and tdT^+^ScxGFP^+^EDU^+^ (*P*=8.95E-03, *P*=0.951, *P*=1.59E-03). **e**, Bar graph for average number of lineage cells in midsubstance; n=3 animals/condition. **f**, Zoomed in fluorescent images of PDGF-AA treated midsubstance (from **e**) stained for FMOD; asterisks, FMOD^+^tdT^+^ScxGFP^+^ cells; 3 independent repeats. **g**, Bar graph of percentage of ER-TR7^+^ sheath cells per treatment; n=3 animals/condition; 3 samples/n. Unpaired two-tailed Student's *t*-test (**c**, **d**, **e**, **f**), error bars = SEM; scale bar = 30 (**d**, **f**) μm.](nihms-1540808-f0005){#F5}

![PDGFRα signaling is required in *Tppp3*^+^ cells for regeneration.\
**a**, H & E histology of *Pdgfra*^fl/fl^ (control) and *Tppp3*^CG/+^;*Pdgfra*^fl/fl^ (cKO) at 30 dpi; white box, area of zoom in panels displayed to the right; arrows, matrix defects; dashed line, midsubstance-sheath boundary; 2 independent repeats. **b**, Picrosirius red histology of *Pdgfra*^fl/fl^ (control) and *Tppp3*^CG/+^;*Pdgfra*^fl/fl^ (cKO) at 14 dpi; black box, area of zoom in panels displayed on the right; arrows, matrix defects; 2 independent repeats. **c**, Experimental scheme and fluorescent images of *Pdgfra*^fl/fl^ (control), *Tppp3*^CG/+^;*Pdgfra*^fl/fl^, and *Tppp3*^ECE/+^;*Pdgfra*^fl/fl^ tendons at 30 dpi; 3 (control) and 4 (mutants) animals/condition; EdU for first 15 d; Col-F, collagen; TNC, antibody stained; dashed line, midsubstance-sheath boundary; arrow, regenerated tendon; asterisk, failed regeneration. **d**, TEM images of control uninjured (CU), control injured (CI), and cKO injured (cKO I) adult, tendon cross-sections of equivalent area. Upper panels are low magnifications of matrix architecture. Red asterisk indicates hole in matrix. White dashed line indicates the border of the injury where fibrils were counted for cKO I. Lower panels represent two images of fibrils per condition. Bar graph, aggregated distribution of collagen fibril diameters, using high magnification TEM images above from n = 4 mice/group (1000 fibrils/tendon for CU and CI, and at least 150 fibrils/tendon for cKO I on the edge of the injury hole). Average minimum feret fibril diameter across tendon types are as follows: 124.7±0.7 (CU), 55.3±0.5 (CI), and 110.6±2.2 (cKO I) (Mean±SEM) nm. Scale bars = 0.2 (**d** lower panels), 10 (**d** upper panels), 50 (**a**, **b, c** zoomed in panels on left) and 100 (**a**, **b** zoomed out panels on right) μm.](nihms-1540808-f0006){#F6}

![*Tppp3*^+^ mutant cells fail to differentiate following injury.\
**a**, *Pdgfra* gene inactivation: Same TMX and injury scheme as before and harvested at 14 dpi; EdU daily throughout. Upper panels, images for *Tppp3*^CG/+^;*R26R*^tdT^ (R-control) and lower panels for *Tppp3*^CG/+^;*R26R*^tdT^;*Pdgfra*^fl/fl^ (R-cKO); asterisk, area of failed regeneration. GFP was detected by immunofluorescence. n=3 (R-control) and n=4 (R-cKO) animals/condition; 3 samples/n. To the upper right, quantification for lineage cells per injury area (unpaired two-tail Student's *t*-test); mean(%)=(R-control, 46.6; R-cKO, 30.7). To the lower right, tdT lineage composition at bottom (Chi-square test \#\# p \<0.01). Each cell fraction is also subjected to unpaired two-tail Student's *t*-test in parentheses between R-control and R-cKO groups: tdT^+^ (*P*=8.00E-13), tdT^+^GFP^+^ (*P*=2.54E-08), tdT^+^GFP^+^EdU^+^ (*P*=3.59E-15), tdT^+^EdU^+^ (*P*=1.27E-12); mean(%) per cell fraction across groups (R-control, R-cKO) as follows: tdT^+^(33.8, 1.7), tdT^+^GFP^+^ (6.8, 24.6), tdT^+^GFP^+^EdU^+^ (6.5, 66.9), tdT^+^EdU^+^ (53.0, 6.8). **b**, SCX immunofluorescence organized as in (**a**); to the right, pie charts for lineage composition; two-way *ANOVA*, *df =* 3, *P* = 6.5776E-20; n=3 samples; 3 independent repeats. **c**, FMOD immunofluorescence organized as in (**a**); dashed line, midsubstance-sheath boundary; 3 independent repeats. **d**, Model: T-FAPs and stem cells reside in the sheath (gray) and tenocytes in the midsubstance (red). Following injury, PDGF signalling directs T-FAPs to elicit fibrosis and stem cells to produce new tenocytes. Tenocytes have limited repair (gray small arrow) and do not compensate without functional stem cells (R-cKO). Error bars = SEM (**a**); scale bar = 50 (**a**, **b**), 100 (**c**) μm.](nihms-1540808-f0007){#F7}

![Sheath subpopulations do not have identical properties *in vitro*\
**a**, Schemes for *in vitro* experiments using cell subpopulations purified from *Tppp3*^CG/+^;*R26R*^tdT^;*Pdgfra*^H2B-eGFP^ Patellar tendon. **b**, Fractions of tdT^+^H2B-eGFP^+^ subpopulation that were TPPP3^+^ or PDGFRα^+^ at specified time intervals in TSPC culture; n=4 samples per time point; Mean per time point (24 h, 72 h, 120 h) indicated fractions of positive marker staining (TPPP3^+^; 0.997, 0.995, 0.997), (PDGFRα^+^, 0.999, 0.996, 0.998). **c**, tdT^−^H2B-eGFP^+^ subpopulation at specified time intervals in TSPC culture; n=4 samples per time point; unpaired two-tail Student's *t*-test p-values displayed on chart; mean per condition (24 h V, 24 h 4-OH, 72 h 4-OH, 96 h 4-OH) as follows: (0.005, 0.006, 0.006, 0.003). **d**, tdT^+^H2B-eGFP^−^ subpopulation at specified time intervals in TSPC culture; n=8 samples per time point; unpaired two-tail Student's *t*-test significant p-values displayed on chart, all other comparisons are non-significant, p \> 0.05; Mean per time (24 h, 48 h, 72, 96 h) as follows: (0.026, 0.010, 0.010, 0.005). **e**, Multipotent differentiation assay: control, non-differentiated murine mesenchymal stem cells (MSCs); scale bars = 50 μm (adipogenesis and osteogenesis), 1000 μm (chondrogenesis). 3 independent repeats. Error bars = SEM (**b**-**d**).](nihms-1540808-f0008){#F8}
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